Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35


Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:

  • Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
  • Combivent Respimat® (ipratropium bromide and albuterol) Inhalation Spray
  • Spiriva HandiHaler(tiotropium bromide inhalation powder)
  • Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray
  • Spiriva® Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray
  • Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray
  • Striverdi Respimat (olodaterol) Inhalation Spray

The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.